Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481).

Trial Profile

Exploratory Study of Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma (AVF3961s) (CRAD001C2481).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Neuroendocrine tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Oct 2011 Actual end date Oct 2011 added as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Planned end date changed from Jan 2012 to Jan 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top